

**TREATING THE MOTHER – PROTECTING THE UNBORN**  
**A MOTHERISK Educational Program**

**Vol. 2**  
**Reference List**

**Section 1 - DIABETES IN PREGNANCY**

- DIA-1 Rosenn B et al. Glycemic thresholds for spontaneous abortion and congenital malformations in insulin-dependent diabetes mellitus. *Obstetrics & Gynecology*. 1994;84(4):515-520.
- DIA-2 Gilbert C et al. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. *Fertil Steril*. 2006 Sep;86(3):658-63.
- DIA-3 Dixon D et al. Gestational diabetes mellitus: an update and review for primary care providers. *Physician Assistant*. March 1999.
- DIA-4 Crowther CA et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *N Engl J Med*. 2005 Jun 16;352(24):2477-86.
- DIA-5 American Diabetes Association. Clinical practice recommendations: Gestational diabetes mellitus. 2001;24(1).
- DIA-6 Briggs G. et al. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk, Seventh Ed. Lippincott Williams & Wilkins. 2005;294-7.
- DIA-7 Langer O et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. *N Engl J Med*. 2000;343(16):1134-1138.
- DIA-8 Gutzin S et al. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis. *Can J Clin Pharmacol*. 2003;10(4):179-83.
- DIA-9 Hellmuth E et al. Oral hypoglycaemic agents in 118 diabetic pregnancies. *Diabetic Medicine*. 2000;17:507-511.
- DIA-10 Berger H et al. Screening for gestational diabetes mellitus. *SOGC Clinical Practice Guidelines*. 2002 Nov: No. 121. <http://www.sogc.org/guidelines/public/121E-CPG-November2002.pdf>

**Section 2 - DEPRESSION IN PREGNANCY**

- MDE-1 Hirschfeld RMA et al. The national depressive and manic-depressive association consensus statement on the undertreatment of depression. *JAMA*. 1997.
- MDE-2 Marcus S. Review Article: Treatment guidelines for depression in pregnancy. *Int J Gynecol Obstet*. 2001;72:67.
- MDE-3 Cohen LS et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. *JAMA*. 2006 Feb 1;295(5):499-507.
- MDE-4 Einarson A et al. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. *J Psychiatry Neurosci*. 2001;26(1):44-48.
- MDE-5 Koren G et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? *CMAJ*. 2005 May 24;172(11):1457-9. <http://www.cmaj.ca/cgi/reprint/172/11/1457>
- MDE-6 Chambers C et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med*. 2006 Feb;354(6):579-87.
- MDE-7 Nulman I et al. Neurodevelopment of children exposed in utero to antidepressant drugs. *N Engl J Med*. 1997;336(4):258-262.

## **TREATING THE MOTHER – PROTECTING THE UNBORN**

### **A MOTHERISK Educational Program**

- MDE-8 Nulman I et al. Child development following exposure to TCAs and fluoxetine throughout fetal life: a prospective controlled study. *Am J Psychiatry*. 2002;159(11):1889-95.
- MDE-9 Einarson A et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. *Am J Psychiatry*. 2001;158(10):1728-1730.
- MDE-10 Nulman et al. Child neurodevelopment following exposure to venlafaxine in utero. *Reprod Toxicol*. 2006;22(2);280.
- MDE-11 Chun-Fai-Chan B et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. *Am J Obstet Gynecol*. 2005 Mar;192(3):932-6.
- MDE-12 Costei AM et al. Perinatal outcome following third trimester exposure to paroxetine. *Arch Pediatr Adolesc Med*. 2002;156(11):1129-1132.
- MDE-13 Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. *Arch Pediatr Adolesc Med*. 2004;158(4):312-6.
- MDE-14 Koren G. Discontinuation syndrome following late pregnancy exposure to antidepressants. *Arch Pediatr Adolesc Med*. 2004;158(4):307-8.

### **Section 3 - MATERNAL NUTRITION & SUPPLEMENTATION – EFFECTS ON PREGNANCY OUTCOME**

- MNU-1 Soldin OP. Controversies in urinary iodine determinations. *Clin Biochem*. 2002 Nov;35(8):575-9.
- MNU-2 Wald NJ et al. Quantifying the effect of folic acid. *Lancet*. 2001 Dec 15;358(9298):2069-73.
- MNU-3 Health Canada. Nutrition for a Healthy Pregnancy: National guidelines for the childbearing years. Ottawa. Minister of Public Works and Government Services Canada. 1999. Minister of Health. [http://www.hc-sc.gc.ca/fn-an/nutrition/prenatal/national\\_guidelines\\_cp-lignes\\_directrices\\_nationales\\_pc\\_e.html](http://www.hc-sc.gc.ca/fn-an/nutrition/prenatal/national_guidelines_cp-lignes_directrices_nationales_pc_e.html)
- MNU-4 Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med*. 1992 Dec 24;327(26):1832-5.
- MNU-5 Radhika MS et al. Effects of vitamin A deficiency during pregnancy on maternal and child health. *BJOG*. 2002;109:689-93.
- MNU-6 Dallaire F et al. Vitamin A concentration in umbilical cord blood of infants from three separate regions of the province of Quebec (Canada). *Can J Public Health*. 2003;94:386-90.
- MNU-7 Godel JC et al. Perinatal vitamin A (retinol) status of northern Canadian mothers and their infants. *Biol Neonate*. 1996;69:133-9.
- MNU-8 Wein EE. Nutrient intakes of First Nations people in four Yukon communities. *Nutr Res*. 1995;15(8):1105-1119.
- MNU-9 Teratology Society position paper: recommendations for vitamin A use during pregnancy. *Teratology*. 1987;35:269-75.
- MNU-10 Van Allen MI et al. Preconception health: folic acid for the primary prevention of neural tube defects. A resource document for health professionals, 2002. Ottawa, Ontario: Minister of Public Works and Government Services Canada. [http://www.phac-aspc.gc.ca/fa-af/report/full\\_report.html](http://www.phac-aspc.gc.ca/fa-af/report/full_report.html)
- MNU-11 Health Canada. Why all women who could become pregnant should be taking Folic Acid. 2003. 2005. <http://www.phac-aspc.gc.ca/fa-af/index.html>
- MNU-12 Wilson RD et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. *J Obstet Gynaecol Can*. 2003;25:959-73. Notes: CORPORATE NAME: Genetics Committee and Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. <http://www.sogc.org/guidelines/public/138E-CPG-November2003.pdf>

**TREATING THE MOTHER – PROTECTING THE UNBORN**  
**A MOTHERISK Educational Program**

- MNU-13 National Institutes of Health. Optimal calcium intake. NIH consensus conference. *JAMA*. 1994 Dec 28;272(24):1942-8.
- MNU-14 Daly LE et al. Folate levels and neural tube defects: implications for prevention. *JAMA*. 1995;274(21):1698-702.
- MNU-15 Joint SOGC-Motherisk Clinical Practice Guideline. Pre-conceptional vitamin/folic acid supplementation 2007: The use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. *JOGC*. 2007 Dec;29(12):1003-13.
- MNU-16 Nguyen P et al. Effect of iron content on the tolerability of prenatal multivitamins in pregnancy. *BMC Pregnancy Childbirth* 2008;8:17.
- MNU-17 Koren G, Goh I. Increasing folate supplementation for selected groups of Canadian women. *J Obstet Gynaecol Can*. 2007 Dec;29(12):992-6.
- MNU-18 Kim YI. Does a high folate intake increase the risk of breast cancer? *Nutr Rev*. 2006 Oct;64(10 pt 1):468-75.
- MNU-19 Navarro Silvera SA et al. Dietary folate consumption and risk of ovarian cancer: A prospective cohort study. *Eur J Cancer Prev*. 2006 Dec;15(6):511-5.
- MNU-21 Bohnsack BL, Hirschi KK. Nutrient regulation of cell cycle progression. *Annu Rev Nutr*. 2004;24:433-53.
- MNU-22 Bung P et al. Folic acid supply in pregnancy – results of a prospective longitudinal study. *Geburtshilfe Frauenheilkd*. 1993;53:92-9.
- MNU-23 Wald NJ et al. Blood folic acid and vitamin B12 in relation to neural tube defects. *Br J Obstet Gynaecol*. 1996;103:319-24.
- MNU-24 Hamaoui E, Hamaoui M. Nutritional assessment and support during pregnancy. *Gastroenterol Clin North Am*. 2003;32:59-121.
- MNU-25 Ravin CR. Fortifying oral contraceptives with folic acid. *AWHONN Lifelines* 2004;8:12-3.  
Notes: CORPORATE NAME: Association of Women's Health, Obstetric and Neonatal Nurses.
- MNU-26 Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. *Placenta*. 1999;20:519-29.
- MNU-27 Scholl TO, Johnson WG. Folic acid: influence on the outcome of pregnancy. *Am J Clin Nutr*. 2000;71:1295S-303S.
- MNU-28 Smits LJ, Essed GG. Short interpregnancy intervals and unfavourable pregnancy outcome: role of folate depletion. *Lancet*. 2001;358:2074-7.
- MNU-29 Bruinse HW, van den Berg H. Changes of some vitamin levels during and after normal pregnancy. *Eur J Obstet Gynecol Reprod Biol*. 1995;61:31-7.
- MNU-30 Health and Welfare Canada. Nutrition recommendations: the report of the scientific review committee. Ottawa: Minister of Supplies and Services Canada; 1990.
- MNU-31 Muggli EE, Halliday JL. Folic acid and risk of twinning: A systematic review of the recent literature, July 1994 to July 2006. *Med J Aust*. 2007 Mar 5;186(5):243-8.
- MNU-32 Hernandez-Diaz S et al. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med*. 2000;343:1608-14.
- MNU-33 Alstead EM. Inflammatory bowel disease in pregnancy. *Postgrad Med J*. 2002;78:23-6.
- MNU-34 Wald NJ. Folic acid and the prevention of neural-tube defects. *N Engl J Med*. 2004;350:101-3.
- MNU-35 von Tempelhoff GF et al. Mean maternal second-trimester hemoglobin concentration and outcome of pregnancy: a population-based study. *Clin Appl Thromb Hemost*. 2008;14(1):19-28.

**TREATING THE MOTHER – PROTECTING THE UNBORN**  
**A MOTHERISK Educational Program**

- MNU-36 Metz J et al. The relationship between serum cobalamin concentration and mean red cell volume at varying concentrations of serum folate. *Clin Lab Haematol.* 2004;26:323-5.
- MNU-37 Goh YI et al. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. *J Obstet Gynaecol Can.* 2006 Aug;28(8):680-9. [http://sogc.com/jogc/abstracts/full/200608\\_Obstetrics\\_3.pdf](http://sogc.com/jogc/abstracts/full/200608_Obstetrics_3.pdf)
- MNU-38 Goh YI et al. Prenatal multivitamin supplementation and rates of pediatric cancers: a meta-analysis. *Clin Pharmacol Ther.* 2007 May;81(5):685-91.
- MNU-39 Institute of Medicine, ed. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium and zinc. Washington DC: National Academy Press. 2001. <http://www.nap.edu/books/0309072794/html/>
- MNU-40 Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. *MMWR Recomm Rep.* 1998;47:1-29.
- MNU-41 Turner RE et al. Comparing nutrient intake from food to the estimated average requirements shows middle- to upper-income pregnant women lack iron and possibly magnesium. *J Am Diet Assoc.* 2003;103:461-6.
- MNU-42 Steinmacher J et al. Randomized trial of early versus late enteral iron supplementation in infants with a birth weight of less than 1301 grams: neurocognitive development at 5.3 years' corrected age. *Pediatrics.* 2007;120(3):538-46.
- MNU-43 Villar J et al. Nutritional interventions during pregnancy for the prevention or treatment of impaired fetal growth: an overview of randomized controlled trials. *J Nutr.* 2003;133:1626S-1631S.
- MNU-44 Delange F. Iodine nutrition and neonatal hypothyroidism. *Rev Med Brux.* 1994;15:359-65.
- MNU-45 Dunn JT. Iodine supplementation and the prevention of cretinism. *Ann N Y Acad Sci.* 1993;678:158-68.
- MNU-46 Hetzel BS, Mano MT. A review of experimental studies of iodine deficiency during fetal development. *J Nutr.* 1989;119:145-51.
- MNU-47 Connolly KJ et al. Fetal iodine deficiency and motor performance during childhood. *Lancet.* 1979;2:1149-51.
- MNU-48 Choudhury N, Gorman KS. Subclinical prenatal iodine deficiency negatively affects infant development in Northern China. *J Nutr.* 2003;133:3162-5.
- MNU-49 Hollowell JG et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). *J Clin Endocrinol Metab.* 1998;83:3401-8.
- MNU-50 International Council for the Control of Iodine Deficiency Disorders. Iodine Nutrition in Canada. 2004.
- MNU-51 Kapur BM et al. Folate fortification and supplementation – Are we there yet? *Can J Clin Pharmacol* 2007;14(2):e178.
- Bar-Oz B et al. Folate fortification and supplementation – Are we there yet? *Reprod Toxicol* 2008 Aug;25(4):408-12.
- MNU-52 First Nations, Inuit and Métis Health Committee, Canadian Paediatric Society (CPS). Vitamin D supplementation: Recommendations for Canadian mothers and infants. *Paediatr Child Health.* 2007;12(7):583-9. <http://www.cps.ca/english/statements/II/FNIM07-01.htm>
- MNU-53 Dubnov-Raz G et al. Omega-3 fatty acid supplementation during pregnancy: for mother, baby, or neither? *Can Fam Physic.* 2007;53(5):817-8.
- MNU-54 Helland I et al. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. *Paediatrics.* 2003;111(1):e39-e44.
- MNU-57 Botto LD et al. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. *Am J Med Genet.* 2004;125C:12-21.

**TREATING THE MOTHER – PROTECTING THE UNBORN**  
**A MOTHERISK Educational Program**

- MNU-58 French AE et al. Folic acid food fortification is associated with a decline in neuroblastoma. *Clin Pharmacol Ther.* 2003;74:288-94.
- MNU-59 Olshan AF et al. Maternal vitamin use and reduced risk of neuroblastoma. *Epidemiology.* 2002;13:575-80.
- MNU-67 Ahn E et al. Iron bioavailability in prenatal multivitamin supplements with separated and combined iron and calcium. *J Obstet Gynaecol Can.* 2004;26:809-14.
- MNU-69 Ahn E et al. Multivitamin supplements for pregnant women. New insights. *Can Fam Physician.* 2004;50:705-6.
- MNU-70 Chopra IJ, Baber K. Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine dose requirement in pregnancy? *Metabolism.* 2003;52:122-8.
- MNU-71 Pletz MW et al. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. *Antimicrob Agents Chemother.* 2003;47:2158-60.

**TO OBTAIN A COPY OF ANY OF THE ABOVE STUDIES:**

**1-888-666-0611**

**[info@drugs-in-pregnancy.org](mailto:info@drugs-in-pregnancy.org)**